FindTrial
Sign In

C000593333

2 trials

Sponsors

Yonemori Kan, ARAKAWA AYUMU

Conditions

Epithelioid Sarcoma Loss of INI1 protein, Epithelioid SarcomaPediatric and AYA malignant solid tumors with no standard therapy or refractory to standard therapy Malignant solid tumors with SWI/SNF complex abnormalities

Phase 2

NCCH2107/MK012 trial
Active, not recruitingJPRN-jRCT2031220523
Yonemori KanEpithelioid Sarcoma Loss of INI1 protein, Epithelioid Sarcoma
Start: 2022-12-20Target: 17Updated: 2026-06-29
NCCH2214 trial (TURTLE trial)
Active, not recruitingJPRN-jRCTs031220736
ARAKAWA AYUMUPediatric and AYA malignant solid tumors with no standard therapy or refractory to standard therapy Malignant solid tumors with SWI/SNF complex abnormalities
Start: 2023-03-27Target: 10Updated: 2026-06-29

Related Papers

Efficacy and safety results of tazemetostat in Japanese patients with advanced epithelioid sarcoma: The phase 2 TAZETTA trial (NCCH2107).
Journal of Clinical Oncology2026-05-27